GSK Sales, Profit Rise on Boost from HIV, Cancer Drugs
In This Article:
GSK’s profit rose on better-than-expected performance of HIV, cancer and asthma treatments, offsetting lower vaccine demand in the U.S.
Oops, something went wrong
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
GSK’s profit rose on better-than-expected performance of HIV, cancer and asthma treatments, offsetting lower vaccine demand in the U.S.